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A B S T R A C T
Several superfamilies of plasma membrane channels which regulate transmembrane ion ﬂux have also been
shown to regulate a multitude of cellular processes, including proliferation and migration. Ion channels are
typically multimeric complexes consisting of conducting subunits and auxiliary, non-conducting subunits.
Auxiliary subunits modulate the function of conducting subunits and have putative non-conducting roles, further
expanding the repertoire of cellular processes governed by ion channel complexes to processes such as trans-
cellular adhesion and gene transcription. Given this expansive inﬂuence of ion channels on cellular behaviour it
is perhaps no surprise that aberrant ion channel expression is a common occurrence in cancer. This review will
focus on the conducting and non-conducting roles of the auxiliary subunits of various Ca2+, K+, Na+ and Cl−
channels and the burgeoning evidence linking such auxiliary subunits to cancer. Several subunits are upregu-
lated (e.g. Cavβ, Cavγ) and downregulated (e.g. Kvβ) in cancer, while other subunits have been functionally
implicated as oncogenes (e.g. Navβ1, Cavα2δ1) and tumour suppressor genes (e.g. CLCA2, KCNE2, BKγ1) based on
in vivo studies. The strengthening link between ion channel auxiliary subunits and cancer has exposed these
subunits as potential biomarkers and therapeutic targets. However further mechanistic understanding is required
into how these subunits contribute to tumour progression before their therapeutic potential can be fully realised.
1. Introduction
Ion channels are heteromeric membrane protein complexes which
permit transmembrane ion conduction. Several ion channels, e.g. K+
channels and voltage-gated Na+ channels (VGSCs), are notable for
regulating membrane potential in excitable cells [1], but an expanding
repertoire of other cellular processes, such as proliferation, diﬀer-
entiation [2], cell volume control and migration [3,4], are also known
to be inﬂuenced by ion channels. Owing to their extensive impact on
cellular function, it is no surprise that ion channel dysregulation is a
common characteristic in cancer [5]. Ion channels are often multimeric,
with ion-conducting subunits accompanied by non-conducting auxiliary
subunits [6]. Auxiliary subunit-mediated modulation of the conducting
subunit is well established but increasing evidence has unveiled a
multitude of non-conducting roles for these proteins as well [7–14]. An
emerging ﬁeld has focused on investigating auxiliary subunits in
cancer, which, like the conducting subunits, are often aberrantly ex-
pressed and could represent novel therapeutic targets. In this review,
we dissect the conducting and non-conducting roles of the auxiliary
subunits of Ca2+, K+, Na+ and Cl− channels and the growing evidence
supporting a link to cancer.
2. Ca2+ channels
Ca2+ channels regulate a multitude of cellular processes; accord-
ingly, much research has focused on various Ca2+ channels in cancer,
including voltage-gated Ca2+ channels (VGCCs) [15], STIM and Orai
[16], and TRP channels [17]. In terms of Ca2+ channel auxiliary sub-
units however, only VGCC auxiliary subunits have received notable
attention thus far. VGCCs are transmembrane complexes responsible for
the inward Ca2+ current seen in excitable cells following depolarisa-
tion, however VGCCs are also expressed in other non-excitable cell
types, e.g. osteoblasts and osteoclasts [18,19]. VGCCs are composed of
a Ca2+-conducting α1 subunit (Cav1-3.x) associated with multiple
auxiliary subunits (α2δ1-4, β1-4, γ1-8), with the exception of Cav3.x,
which can form a T-type Ca2+ channel in the absence of an associated
https://doi.org/10.1016/j.ceca.2019.04.005
Received 12 March 2019; Received in revised form 16 April 2019; Accepted 16 April 2019
Abbreviations: BK, large-conductance calcium-activated potassium channel; CaCC, calcium-activated chloride channel; CAM, cell-adhesion molecule; CLC, voltage-
gated chloride channel; CLCA, chloride channel accessory; DREAM, downstream regulatory element antagonistic modulator; GIRK, G-protein inwardly rectifying
potassium channel; KChIP, potassium channel interacting protein; Kir, inwardly-rectifying potassium channel; SUR, sulfonylurea receptor; VGCC, voltage-gated
calcium channel; VGKC, voltage-gated potassium channel; VGSC, voltage-gated sodium channel
⁎ Corresponding author at: University of York, Wentworth Way, Heslington, York, YO10 5DD, UK.
E-mail address: william.brackenbury@york.ac.uk (W.J. Brackenbury).
&HOO&DOFLXP²
$YDLODEOHRQOLQH$SULO7KH$XWKRUV3XEOLVKHGE\(OVHYLHU/WG7KLVLVDQRSHQDFFHVVDUWLFOHXQGHUWKH&&%<OLFHQVHKWWSFUHDWLYHFRPPRQVRUJOLFHQVHV%<
7
auxiliary subunit (Fig. 1) [20]. A Cav1/2 subunit is joined at the
membrane by an α2δ-, β-, and potentially a γ-subunit, although γ-sub-
units are not always precipitated with Cavα [21]. Cavα1 subunits have
an oncogenic inﬂuence in cancer [15]. Research into Cav auxiliary
subunits in cancer is a growing ﬁeld, but it appears Cav auxiliary sub-
units have both oncogenic and tumour-suppressive eﬀects.
2.1. CaVβ
The VGCC β-subunits are cytoplasmic proteins that interact with the
α1 DI-DII intracellular linker region [22–24]. β-subunit binding en-
hances membrane expression of α1 subunits [25,26], however the
mechanism by which this occurs has not yet been elucidated. It is
thought that β-subunit binding prevents ER retention and the sub-
sequent degradation of Cav2.2, resulting in a higher proportion of
Cav2.2 at the plasma membrane [25,27]. However, membrane targeting
of the DI-DII linker of Cav2.2 via an inserted palmitoylation motif still
results in ER retention and degradation, leading to the hypothesis that
Cavβ subunits are required for correct folding, and thus membrane in-
sertion, of functional α1 subunits [28]. The impact on electro-
physiological properties of α1 subunits by Cavβs is complex. In general,
Cavβs increase current density and regulate activation/inactivation ki-
netics. For instance, disruption of the Cavβ3-CaV2.2 interaction by a
small molecule inhibitor results in a decrease in current density and a
depolarised shift in the voltage threshold of activation and inactivation
[29]. In comparison, Cavβ2 enhances the current density more than
Cavβ3, potentially through increased membrane expression as Cavβ2a,
unlike Cavβ3, contains a palmitoylation site [30]. Additionally, forced
membrane localisation of Cavβ3 using the N-terminal Lyn sequence
enhanced the current density relative to WT- Cavβ3 [30]. The com-
plexity arises in the diﬀerential sensitivity to PIP2-mediated modulation
of diﬀerent Cavβs [30,31], competition for α1-binding between Cavβ
subunits [32], the spectrum of functionally-distinct Cavβ splice variants
[33,34], and the opposing impacts on α1-function by the diﬀerent do-
mains within the Cavβ protein [35].
Cavβs are functional independent of direct α1 association. All Cavβs
demonstrate nucleus localisation, Cavβ4 particularly within nucleoli,
and gene expression regulation [36–39]. All Cavβs also contain a Src
homology 3 domain capable of regulating endocytosis via interaction
with dynamin and can interact with small GTPases [40,41]. Cavβs show
subunit-speciﬁc function as well, for instance Cavβ1 is expressed in
muscle progenitor cells (MPCs) earlier than Cav1.1, where it regulates
proliferation and directly suppresses myogenin expression. Accord-
ingly, Cavβ1 knockout mice demonstrate impaired muscle development
[36,42]. Similarly, Cavβ2 is required for ventricle cell proliferation and
heart development in zebraﬁsh, although pharmacological VGCC in-
hibition caused a similar phenotype, suggesting Cavβ2 may be func-
tioning in an α1-dependent manner [43]. Cavβ2 is also required for
depolarisation-induced c-Fos and meCP2 activation, which intriguingly
was shown to be independent of Ca2+ inﬂux [37]. Cavβ4 regulates cell
proliferation in vitro [44], downregulates Wnt signalling via seques-
tration of the Wnt pathway eﬀector TCF4 [39], and regulates gene
expression via various interacting partners [45,46]. Interestingly, the
nuclear localisation of Cavβ4 was inhibited when co-expressed with
Cav1.1 and only upon depolarisation and the presence of extracellular
Ca2+ did Cavβ4 interact with its nuclear signalling partner, B56δ [45].
Owing to its role in driving cellular functions such as proliferation
and migration, it is perhaps no surprise that CaVα1 expression is in-
creased in various cancers [47–49]. However, much research has also
been dedicated to evaluating the involvement of Cav auxiliary subunits
in cancer. Cavβ1 expression is upregulated in colon cancer [50], Cavβ2
mutations are seen in bladder cancer [51] and increased Cavβ3 ex-
pression is observed in patients with recurrent non-small cell lung tu-
mours compared to recurrence-free patients [52]. Furthermore, ex-
pression of Cavβ1 and Cavβ3 are included in proposed high-risk gene
signatures that correlate with decreased patient survival in colon and
recurring non-small cell lung cancer [50,52]. However, the aforemen-
tioned studies are largely limited to statistical observations based on
tissue sequencing data that identiﬁed altered Cavβ RNA expression as a
high-risk prognostic marker [50–52]. Chen et al. (2016) oﬀered addi-
tional pathophysiological justiﬁcation for increased Cavβ2 expression in
cancer, by observing an enrichment in mutations of genes, including
CACNB2 which encodes Cavβ2, involved in NCAM-mediated neurite
outgrowth [51].
2.2. α2δ
The CaV α2δ subunit has a unique structure compared to other
auxiliary subunits. The translated polypeptide is proteolytically cleaved
into two separate proteins, α2 and δ, which remain coupled by a dis-
ulphide bond [53]. The α2 segment is extracellular while the δ-subunit
remains associated with the membrane via a GPI-anchor [54]. α2δ and
CaVβ subunits can both induce surface expression of α1, but also
function synergistically to maximise α1 surface expression and Ca
2+
current [26,55,56]. Preventing proteolytic cleavage of the α2δ1 pro-
protein reduces both Cav2.2 surface expression and presynaptic Ca
2+
inﬂux in hippocampal neurons [57] and site-directed mutagenesis of
either cysteine residue involved in the disulphide interaction, which
results in a dissociation of α2, reduces the whole-cell Ca
2+ current [53].
Similarly, digestion of the GPI anchor of α2δ3, by prokaryotic
Fig. 1. Voltage-gated Ca2+ channel auxiliary subunits.
Voltage-gated Ca2+ channels (VGCCs) are composed of a
conducting α1 subunit accompanied and functionally modu-
lated by Cavβ, α2δ and Cavγ subunits [20]. α1 consists of four
domains (domains I-IV), each consisting of six segments (S1-
S6). The voltage-sensing domain is found within S4 of each
domain and the pore consists of the P-loop found between S5-
6 of each domain. Cavβ modulates Ca
2+ inﬂux via binding the
DI-DII linker of α1. Cavβs are also involved in regulating gene
expression and endocytosis [22,36–38,40,44]. α2δ subunits
are extracellular proteins that remain associated to the mem-
brane via a GPI-anchor [54]. α2δ subunits are involved in
synaptogenesis [65]. Cavγ subunits are four-pass transmem-
brane proteins also involved in cervical ganglion neurite
outgrowth and synaptogenesis [108,109].
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phosphatidylinositol-phospholipase C, results in a release of the α2δ
from the membrane and a decreased Ca2+ current [54]. Both these
results suggest an intact α2δ subunit is required at the membrane to
induce and sustain the α2δ-mediated regulation of α1 subunits. In ad-
dition to its role in traﬃcking, α2δ has been proposed to stabilise α1 at
the membrane by reducing internalisation and in targeting α1 to de-
tergent-resistant membranes [54,58]. Phenotypes of α2δ knockout mice
have been very informative, both α2δ1 and α2δ3 have thus been im-
plicated in neuropathic pain, with α2δ1-overexpressing mice demon-
strating hyperalgesia [59] and α2δ3 -knockout mice demonstrating an
enhanced insensitivity to pain [60]. Mice deﬁcient in α2δ2, the isoform
found overwhelmingly in cerebellar Purkinje neurons, present with
seizures and ataxia [61]. Gabapentin, used in the treatment of epilepsy
and neuropathic pain, preferentially binds to α2δ1/2 and lowers α2δ
surface expression, demonstrating that the α2δ auxiliary subunit is a
druggable target [62–64]. All α2δ subunits are involved in synapto-
genesis, but potentially through diﬀerent mechanisms [65]. α2δ1 pro-
motes cortical synaptogenesis, independently of Ca2+ inﬂux, through
binding to secreted astrocytic thrombospondin in the postsynaptic
membrane and promoting actin remodelling via Rac-1 [66], whereas
loss of α2δ4 causes impaired retinal synaptogenesis, which correlates
with a decrease in presynaptic Cav1.4 [67,68].
More is known about the involvement of α2δ subunits in cancer
compared to the other Cav auxiliary subunits. Increased α2δ1 expression
occurs in both ovarian and hepatocellular tumour-initiating cells and
correlates with decreased overall survival and a shorter progression-
free survival in clinical ovarian samples [69–71]. Zhao et al. developed
a monoclonal antibody against α2δ1, 1B50-1 [71]. Sorting of a 1B50-1-
positive subpopulation of Hep-11 cells, a hepatocellular carcinoma
(HCC) cell line, resulted in a subset of cells that initiated tumour for-
mation in all implanted mice, whereas the 1B50-1-negative sub-
population failed to form any tumours. Furthermore, 62/86 of HCC
samples were 1B50-1-positive compared to 0/6 normal tissue samples.
in vivo experimentation demonstrated that administering 1B50-1 re-
duced tumour volume following implantation of two HCC cell lines and
increased survival, especially when co-administered with doxorubicin,
compared to doxorubicin or 1B50-1 alone. Lastly, in vitro work in the
same study demonstrated α2δ1 to be involved in maintaining cell via-
bility and spheroid formation, via increasing Ca2+ inﬂux through L-
type and N-type Ca2+ channels and MAPK signalling [71]. In non-small
cell lung cancer cells, α2δ1 expression confers radioresistance in vitro,
by enhancing the DNA repair response, and chemoresistance in vivo,
potentially through MAPK signalling [72,73]. In addition, various
miRNAs that are downregulated in cancer target α2δ1 expression, in-
cluding hsa-miR-208a-3p and hsa-miR-1207-5p in medulloblastoma
[74], and miR-107 in chronic myeloid leukaemia (CML) [75]. Over-
expressing miR-107 promotes diﬀerentiation in CML cell lines, which is
reversed when expression of α2δ1 is restored [75].
The involvement of α2δ2 in cancer is complex, as α2δ2 can be both
oncogenic and tumour suppressive [76,77]. α2δ2 was initially identiﬁed
as a potential tumour suppressor gene as it is encoded by CACNA2D2,
which is absent in the 3p21.3 chromosomal deletion commonly ob-
served in lung and breast cancer [78]. Similarly, CACNA2D2 is deleted
in cervical carcinoma [79], is commonly methylated in head and neck
squamous cell carcinoma [80], is downregulated in lung squamous cell
carcinoma via miR-205 [81], and its expression correlates with im-
proved survival in patients with lung adenocarcinoma [82]. Function-
ally, in vitro experiments using various non-small cell lung cancer cell
lines have demonstrated that overexpression of α2δ2 induces apoptosis
via mitochondrial cytochrome-c release and subsequent caspase acti-
vation [77]. In contrast, α2δ2 overexpression occurs in prostate tumours
[76] and in insulin-secreting pancreatic adenomas, where elevated in-
tracellular Ca2+ is known to stimulate β-cell proliferation [83]. Fur-
thermore, α2δ2 overexpression in prostate cancer cells induces tu-
mourigenesis and angiogenesis in mice, which is treatable by
administering the α2δ2 inhibitor, gabapentin [76].
Conversely, α2δ3 is considered a tumour suppressor gene, as
downregulation or deletion is seen in nasopharyngeal cancer [84],
breast cancer [85], oesophageal squamous cell carcinoma [86,87],
gastric cancer [88,89], lung cancer [90] and cholangiocarcinoma [91].
Mice implanted with cancer cells overexpressing α2δ3 show a decreased
tumour volume, compared to implanted control cells, in nasophar-
yngeal cancer [84], oesophageal cancer [87] and glioma [92] models.
The consensus mechanism points towards an inhibition of motility and
invasion by α2δ3, and induction of apoptosis through an increase in
intracellular Ca2+, leading to mitochondria-induced apoptosis
[84,87,92].
2.3. CaVγ
The interaction between CaVγ-subunits and α1 subunits is less well
understood. Cavγ-subunits were originally identiﬁed following im-
munoprecipitation of the skeletal muscle 1,4-dihydropyridine (DHP)
receptor (later known as L-type VGCCs), which yielded γ1 as a binding
partner [93,94]. Following the discovery of CaVγ1, seven more Cavγ-
subunits were identiﬁed by homology studies [95–98]. Cavγ2 and Cavγ3
have been shown to associate with Cav2.1 [99], Cavγ2-4 to Cav2.2 [99]
and Cavγ6 to Cav3.1 [100]. Using cryo-electron microscopy, the γ-sub-
unit was predicted to interact with the Cav1.1 voltage-sensing domain
(S4) of domain IV [24]. However, the α1-γ coupling remains con-
tentious as more recent eﬀorts failed to precipitate a Cavγ-subunit with
Cav2. Further, Cavγ2 can regulate Cav2.2 indirectly, suggesting a direct
coupling may not be necessary for Cavγ-induced channel modulation
[21,101]. Cavγ-subunit mRNA is expressed in skeletal muscle (γ1,6,7)
and brain (γ2-8) as well as other tissues such as kidney, liver, colon,
testis and lung [98]. Functionally, Cavγ-subunits negatively regulate
VGCC-mediated Ca2+ inﬂux by decreasing channel expression and
current amplitude [102], hyperpolarising the voltage threshold of in-
activation, accelerating channel inactivation [103], and increasing the
time taken for recovery from inactivation [96]. Cavγ-induced regulation
of Ca2+ inﬂux observed at the cellular level is supported by the Star-
gazer mouse mutant, which lacks Cavγ2 and presents with ataxia and
absence seizures [104]. Interestingly, a subclass of Cavγ-subunits, γ2/3/
4/5/8 (known as transmembrane AMPA receptor regulatory proteins
[TARPs]), which localise to the brain [105], interact with ionotropic
AMPA receptors and induce membrane localisation [106,107]. Other
functions of γ-subunits include Cavγ7-induced neurite outgrowth in
superior cervical ganglion neurons [108] and Cavγ2-induced synapto-
genesis [109].
Aberrant Cavγ expression is seen in various cancers, including in-
creased Cavγ1 in early progressing human epidermal growth factor-
positive (HER2+) metastatic breast cancer [110], increased Cavγ4 in
bladder squamous cell carcinoma [111] and increased Cavγ7 in leio-
myoma via downregulation of miR-197 [112]. Furthermore, a predic-
tion algorithm using a dataset of 1.7 million cancer mutations identiﬁed
Cavγ3 as a putative oncogene [113]. Similar to Cavβ, the functional role
of Cavγ in cancer is not yet clear. However, a Cavγ4 mutation appears in
a cluster of mutations involved in MAPK signalling [111], suggesting a
possible role in regulation of mitogenesis.
In summary, although Cavα1 subunits have an oncogenic role [15],
it is not yet clear whether Cav auxiliary subunits function through Cavα1
or have secondary functions in cancer, or both. Given that Cavβ and
Cavγ are both oncogenic but have antagonistic eﬀects on α1 function,
and Cavα2δ can be oncogenic or tumour suppressive, it would seem that
the involvement of auxiliary subunit-mediated Ca2+ inﬂux in cancer is
tumour type/stage-speciﬁc, dependent on the expression proﬁle of
other subunits, or subordinate to a secondary function of the auxiliary
subunit. Cav auxiliary subunits have functions, potentially α1-in-
dependent, that could contribute to oncogenesis and tumour progres-
sion. All Cavβs regulate gene expression and interact with small
GTPases [36–38,40,41,44]. Cavβ1 and Cavβ2 are also essential for
maintaining proliferation and cellular plasticity during development
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[36,43]. The TARP family of Cavγs induce AMPA receptor membrane
traﬃcking [107], a receptor with an emerging involvement in cancer
[114,115], and Cavγ4 and Cavγ7 induce transcellular adhesion and
neurite outgrowth respectively [108,109]. α2δ1 is also involved in
transcellular adhesion [66]. Furthermore, increased Ca2+ conductance
potentially underpins both the oncogenic function of α2δ1 and α2δ2
[71,83] and the tumour suppressive function of α2δ2 and α2δ3 [77,92].
3. K+ channels
K+ channels represent an extensive superfamily of channels, many
of which have been implicated in regulating key elements of tumour
progression [116–118]. Here, we focus on the function and involve-
ment in cancer of the auxiliary subunits of the voltage-gated K+
channel (VGKC), BK channel and Kir channel complexes (Fig. 2A-C).
VGKC α-subunits represent a diverse family of forty K+-conducting
proteins, Kv1-12.x, which conduct an outward K
+ current in response
to depolarisation of the membrane potential. Three classes of VGKC
auxiliary subunits have been identiﬁed: Kvβ1-3, KChIP1-4, and KCNE1-5
which canonically interact with Kv1, KV4, and Kv7.1 respectively
[119–122], although Kvβs and KCNEs interact with other VGKC α-
subunits and KVβs also interact with TRPV1 and K2P2.1 [123–126]. The
activity of Kv1 [116,127], Kv4 [128], and Kv7.1 [129] is upregulated in
various cancers. However, the expression pattern of VGKC auxiliary
subunits in cancer is more complex.
3.1. Kvβ
Kvβ subunits are cytoplasmic proteins, which form homo- or het-
erotetramers [130] that are involved in traﬃcking of Kv1 and Kv4.3 to
the cell surface [131–133]. Additionally, Kvβ2 is involved in targeted
axonal traﬃcking of Kv1.2 and Kvβ1 diﬀerentially regulates the Kv
composition in ventricular myocytes [134,135]. Kvβ1 and Kvβ3 mod-
ulate VGKC α-subunits via an N-terminal ball domain, which permits
rapid inactivation of delayed-rectifying Kv1 α-subunits [136,137]. Kvβ1
also slows deactivation, accelerates slow inactivation and hyperpo-
larises activation of Kv1.2 [138]. Kvβ2 lacks the ability to inactivate
delayed-rectifying Kv1 channels, but does hyperpolarise channel acti-
vation [139]. Kvβ1 and Kvβ2 are both expressed in developing rat heart
and skeletal muscle and during induced myogenesis of L6E9 cells [140].
Furthermore, deletion of Kvβ1 results in aberrant cardiac electrical ac-
tivity and cardiac hypertrophy in female mice [141]. Kvβ2 deletion
leads to reduced Kv1.5 surface expression in coronary arterial myocytes
and a reduction in total skeletal muscle volume, potentially mediated
through downregulation of Pax7 and upregulation of NEDD4
[133,142]. Interestingly, Kvβs are part of the aldo-keto reductase (AKR)
superfamily owing to their C-terminal AKR domain. The AKR domain
allows for binding and functional modulation by pyridine nucleotides
(NAD and NADP). NADP+ inhibits KVβ1- and KVβ3-mediated inactiva-
tion of Kv1.5 as well as inhibiting Kvβ2-mediated hyperpolarisation of
Kv1.5 activation [143,144].
Evidence suggests that Kvβs are downregulated in cancer. Kvβ1 is
downregulated in malignant thyroid carcinomas relative to benign
thyroid adenomas [145,146]. The gene encoding Kvβ2 is the most sig-
niﬁcant site of methylation in non-functional (non-hormone secreting)
pituitary adenoma compared to functional (hormone-secreting) ade-
nomas and is one of the genes ablated in the common 1p36.3 chro-
mosome deletion seen in neuroblastoma [147,148]. Methylation of the
promoter of the gene encoding Kvβ3 is seen in oral squamous cell
cancers relative to adjacent normal tissue [149]. Together, these data
suggest Kvβs are tumour suppressor genes, but in depth in vitro and in
vivo characterisation of Kvβ in cancer is still currently lacking.
3.2. KCNE
KCNEs are single-pass transmembrane proteins that interact
Fig. 2. K+ channel auxiliary subunits. (A) Voltage-gated K+ channels (VGKCs).
The conducting subunit, Kvα forms tetramers within the membrane that are
accompanied and functionally modulated by four Kvβs (for Kv1), four KChIPs
(for Kv4) or two KCNEs (Kv7.1) [119–122]. The function of Kvβ is modulated by
pyridine nucleotides [143]. KChIPs are involved in regulating gene expression
[173]. (B) Large conductance Ca2+-activated K+ (BK) channels. BK channels
consist of a K+-conducting, seven-pass (S0-S6) membrane protein subunit
(BKα/Slo) accompanied and modulated by dual-pass BKβ and BKγ [182,187].
S0 of BKα is required for interaction with BKβ, S4 is involved in voltage-sen-
sing, the pore region is formed by the linker of S5-6 and an enlarged C-terminus
containing two RCK (regulator of conductance of K+) domains sense in-
tracellular Ca2+ [330]. (C) Inwardly rectifying K+ (Kir) channels. Tetrameric
Kir6 subunits, containing the K
+-conducting pore, are functionally regulated at
the membrane by 17-pass SUR subunits (1:1 stoichiometry), which confer ATP-
sensitivity onto Kir6 via NBDs (nucleotide binding domains) [196]. Kir1-4 can
be bound and modulated by various C-terminal binding proteins [331].
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primarily with Kv7; two KCNEs interact with tetrameric Kv7 [150]. In
vitro studies document a range of eﬀects of KCNEs on Kv7.1. For ex-
ample, KCNE1 and KCNE3 both increase surface expression and current
density, while KCNE4 and KCNE5 have no eﬀect on current density
[151]. KCNE2 and KCNE3 interaction with Kv7.1 produces voltage-in-
sensitive channels and all KCNEs depolarise the activation voltage of
Kv7, with KCNE4 and KCNE5 depolarising activation to a non-physio-
logical membrane potential [151]. KV7.1 has a well-established role in
cardiac rhythm and in regulating osmotic and salt transport across
gastrointestinal, cochlear and renal epithelia; this is reﬂected in Kcne1
knockout mice demonstrating atypical QT intervals, hair cell degen-
eration, impaired renal ﬂuid, glucose and electrolyte uptake, and faecal
Na+ and K+ wasting [152–155]. Furthermore, mutations in KCNE1
underlie Long QT Syndrome 5 and Jervis and Lange-Nielsen syndrome,
a disorder characterised by deafness and cardiac arrhythmia [156,157].
With regard to cancer, KCNE1-3 are expressed in uterine cancer cell
lines, in which they inﬂuence proliferation [158] and a 5-fold and 3-
fold upregulation of KCNE3 and KCNE4 respectively has been reported
in gliobastoma datasets [159]. Paradoxical to the upregulation of
KCNE1 in uterine cancer cell lines, KCNE1 overexpression in an astro-
glioma cell line (U87-MG) induces apoptosis and KCNE1 is one of the
four genes deleted in the 21q22.12 microdeletion which causes a pre-
disposition to acute myelogenous leukaemia [160,161]. The apoptotic
inﬂuence of KCNE1 in U87-MG cells is proposed to occur through ca-
nonical K+ eﬄux through Kv7.1, inducing decreased cytoplasmic K
+, a
known apoptotic trigger [160,162], whereas KCNE1 induces uterine
cancer cell proliferation via modulation of HERG channels [158,163].
HERG channels induce proliferation in a range of cell lines and HERG
channel inhibition decreases MAPK phosphorylation and c-fos expres-
sion in MDA-MB-435S cells [164]. Out of all the Kv auxiliary subunits
however, KCNE2 has the most established link to cancer. KCNE2
downregulation is observed in gastric cancer tissue and gastric cancer
cell lines, correlates with gastritis cystica profunda development (pre-
neoplastic condition characterised by large gastric cysts) and is a risk
factor in gastric cancer stratiﬁcation [165–167]. Furthermore, Kcne2
knockout mice display a 6-fold increase in stomach size, an upregula-
tion of Ki67 and Cyclin D1 in gastric mucosa, an increase in the me-
taplastic marker TFF2, pyloric adenomas and neoplastic invasion
compared to wild-type mice [168]. Overexpression of KCNE2 in the
SGC7901 gastric cancer cell line reduces proliferation and signiﬁcantly
reduces xenograft tumour volume compared to parental SGC7901 cells
[167].
KCNE2-Kv7.1 complexes, in the apical membrane of non-excitable
gastric parietal cells, are essential for maintaining acidiﬁcation of the
stomach, as KCNE2 transforms Kv7.1 to a constitutively open channel
that is potentiated by extracellular H+ [169]. Luminal K+ released by
KCNE2-Kv7.1 is then recycled back into the parietal cell, in exchange
for H+, via the H+/K+ ATPase, resulting in gastric acidiﬁcation
[169,170]. Kcne1 knockout mice demonstrate reduced H+ secretion,
reduced gastric acidiﬁcation, gastric hyperplasia and atypical Kv7.1
localisation [170]. However, it is not yet known whether KCNE2
downregulation contributes to gastric cancer progression through a
failure to acidify the lumen of the stomach or via its role in regulating
tumour cell proliferation.
3.3. KChIP
Ca2+-sensing Kv channel interacting proteins (KChIPs) are involved
in KV4 channel modulation. KChIPs increase surface channel density,
hyperpolarise the voltage of activation, slow inactivation and accelerate
the recovery from inactivation [119,171]. KChIPs were identiﬁed by a
yeast 2-hybrid screen searching for interaction partners with Kv4.2/3 N-
termini [119]. Interestingly, KChIP3 was already known as calsenilin/
downstream regulatory element antagonistic modulator (DREAM).
KChIP3/DREAM plays a key role in diﬀerentiation and apoptosis in-
dependently of K+ channels [172]. DREAM binds upstream genetic
elements (DRE sites) as a tetramer and represses transcription of the
downstream gene until upon Ca2+ stimulation, DREAM tetramers dis-
sociate from DNA allowing gene transcription [173]. Despite KChIP3
being the ﬁrst Ca2+-sensing transcriptional repressor identiﬁed, the
other KChIPs are also capable of DRE-site binding [174]. DREAM ex-
pression is required for maintenance of human embryonic stem cell
pluripotency; DREAM knockdown by siRNA results in an increase in
apoptosis and spontaneous diﬀerentiation [172]. Potentially in-
dependent of its nuclear role, DREAM expression induces Ca2+-medi-
ated apoptosis possibly through sequestration of hexokinase I from
mitochondria [175,176]. Additionally, DREAM expression induces
process outgrowth in pheochromocytoma PC12 cells by RhoA in-
activation and induces thrombus formation in anucleate platelets via
PI3K stimulation [177,178]. There is currently limited evidence of a
role for KChIPs in cancer. However, one study identiﬁed KChIP4 gene
disruption in a renal cancer cell chromosomal break [179]. In addition,
KChIP1 upregulation and KChIP3 downregulation have been shown in
glioblastoma multiforme, with KChIP2 upregulation correlating with
decreased survival for glioblastoma patients [180]. The involvement of
KChIP3/DREAM in regulating diﬀerentiation, apoptosis, transcellular
adhesion and process outgrowth suggests cancer-expressed or down-
regulated KChIPs could be a worthwhile subject of further study.
3.4. BK channels
Large conductance Ca2+-activated K+ (BK) channels are seven
membrane-pass K+ channels that conduct a particularly large outward
K+ current synergistically in response to membrane depolarisation and
a rise in intracellular Ca2+ ([Ca2+]i) [181]. BK channels can be sti-
mulated by depolarisation or increased [Ca2+]i alone, however the
required membrane potential (V1/2=168mV at [Ca
2+]i = 0) or
[Ca2+]i (EC50 ≥10 μM at resting membrane potential) are out of phy-
siological range [182]. BK channels are expressed in most tissues and
are involved in a range of functions, such as learning and memory
[183], pain modulation [184] and blood pressure regulation [185]. BK
channels are upregulated in glioblastoma primary cells and promote
proliferation and invasion [117,186]. BK channel function is modulated
by two groups of auxiliary subunits- BKβ1-4 and BKγ1-4, both double-
pass membrane proteins. BKβ1 and BKβ2 increase Ca
2+ sensitivity
[187], BKβ2 hyperpolarises and accelerates channel activation [188],
BKβ3 depolarises channel activation [188] and BKβ4 hyperpolarises
channel activation whilst simultaneously inhibiting channel opening at
low [Ca2+]i but enhancing activation at high [Ca
2+]i [189]. BKγ sub-
units hyperpolarise BK channel activation [190]. BKγ1 hyperpolarises
channel activation to such an extent (−140mV in LNCaP prostate
cancer cells) that BK channels open without the need for increased
[Ca2+]i at resting membrane potentials [182].
Despite the extensive involvement of BK channels in a range of
physiological processes, the link between BK channel auxiliary subunits
and cancer is still very tentative, with thus far only BKγ1 implicated.
There are conﬂicting reports on the involvement of BKγ1 (also known as
LRRC26 and CAPC) in cancer. BKγ1 is upregulated in the MDA-MB-456
breast cancer cell line and in metastatic secondary breast cancer tu-
mours compared to the primary tumour of a single patient [191]. BKγ1
is also upregulated in many breast and prostate cancer cell lines and
breast, prostate, colon and pancreatic samples [192,193]. However,
BKγ1 is frequently methylated in triple-negative breast cancer speci-
mens and cell lines and siRNA knockdown of BKγ1 in the triple-negative
HCC70 breast cancer cell line enhances anchorage-independent growth,
invasion, migration, and NF-κB activity [194]. Similarly, knockdown of
BKγ1 expression enhances anchorage-independent growth in LNCaP
cells and overexpression of BKγ1 in the triple-negative MDA-MB-231
breast cancer cell line downregulates NF-κB activity and inhibits tu-
mourigenesis and metastasis in nude mice [195]. Furthermore, BKγ1
expression is lowest in poorly diﬀerentiated and highly invasive pros-
tate and breast cancer lines [195]. Thus, BKγ1 appears to have
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oncogenic and tumour-suppressive function depending on the cancer
type. At this stage, the mechanism by which BKγ1 performs these
functions in cancer cells is unclear. BK channels may thus perform
multiple functions in cancer cells, dependent on, or independent of,
BKγ1.
3.5. Kir channels
Inwardly-rectifying K+ (Kir) channels are double pass membrane
proteins which form tetramers in the membrane [196]. Kir channels
lack a voltage sensor domain. IKir is instead dictated by the electro-
chemical gradient and an increasing intracellular blocking of the pore
when the membrane potential (Em)> EK, resulting in an inward IK
when Em<EK and an outward IK when Em>Ek, which is progressively
blocked as Em rises [197]. Kir channels are therefore important for
maintenance of the hyperpolarised resting membrane potential and
regulating activity in excitable cells, such as vascular smooth muscle
[198], central neurons [199] and cardiomyocytes [200]. Subfamilies of
Kir channels exist that are ATP-sensitive (KATP channels; Kir6.x) and G-
protein gated (G-protein inwardly rectifying K+ channels- GIRKs;
Kir3.x) [201,202]. KATP channels are inhibited by ATP/stimulated by
ADP. They function as metabolic sensors, for instance in smooth muscle
where KATP channels regulate vascular tone [203]. GIRKs facilitate G-
protein-mediated inhibitory neurotransmitter signalling, such as GABA
signalling [204,205].
Certain Kir channels are regulated by auxiliary subunits. Kir6 binds
sufonylurea receptors (SUR) 1 or 2 in an octameric conformation (tet-
rameric Kir6 plus tetrameric SUR) to form a KATP channel [196].
Channel assembly is required before KATP is released from the en-
doplasmic reticulum [206]. SUR subunits impart diﬀerential sensitivity
to ADP/ATP and are the binding target of sulfonylureas, a common
form of treatment for type 2 diabetes mellitus [207,208]. SUR1 is
overexpressed in cerebral metastases where it decreases vascular per-
meability [209]. Resveratrol binds to and inhibits SUR1, inducing
apoptosis in HEK293 cells, suggesting a potential pro-survival function
of SUR1 [210]. SUR2B expression is present in leiomyoma and meta-
static breast cancer cells and glibenclamide, a sulfonylurea targeting
SUR proteins, inhibits proliferation in these cells [211,212]. SUR2 ex-
pression, along with Kir6.2, is upregulated in cervical cancer biopsies
[213]. In addition, the eﬀectiveness of glibenclamide at inhibiting
proliferation correlates with the Kir6.2 expression of the cell line tested,
suggesting proliferation is dependent on SUR and Kir6.2 activity [213].
Glibenclamide also inhibits proliferation in MDA-MB-231 breast cancer
cells, inducing G0/G1 cell cycle arrest through an upregulation of P27
and reduction of cyclin E [212]. Treatment of MDA-MD-231 cells with
the KATP channel opener, minoxidil, conversely induces proliferation,
suggesting K+ inﬂux underlies KATP-regulated proliferation [212].
Glibenclamide treatment also prevents tumour growth in vivo in
Sprague-Dawley rats treated with N-nitroso-N-methylurea [214]. Fur-
thermore, in insulinoma, a pancreatic β-cell cancer characterised by
insulin release, which is regulated by KATP channels, SUR1 expression is
increased [215]. In summary, SUR subunits appear to play an onco-
genic role in a Kir-dependent manner.
4. Na+ channels
There is a growing body of evidence supporting a role for Na+
channels in regulating various aspects of cancer progression [216,217].
With regard to auxiliary subunits, however, only those of the VGSC
have been characterised to date and will therefore be the focus of this
section (Fig. 3).
4.1. Voltage-gated Na+ channels
VGSCs conduct an inward Na+ current in response to membrane
depolarisation [218]. VGSCs are composed of a pore-forming α-subunit
(Nav1.1–1.9) and auxiliary β-subunits (Navβ1-Navβ4). Navβs are single
pass transmembrane glycoproteins that bind Navα covalently, in the
case of Navβ2 and Navβ4 [219,220], or non-covalently, in the case of
Navβ1 and Navβ3 [221–223]. INa is responsible for propagation of action
potentials and mutations in Navβs underlie certain types of epilepsy
[224] and cardiac arrhythmia [225]. Navβ1-3 traﬃc Navα to the cell
surface [226–228] and all Navβs increase INa [229–231]. Navβs induce
other changes in Navα gating kinetics, including accelerated recovery
from inactivation [232,233] and accelerated inactivation [230,234].
Navβs can both positively and negatively shift the voltage of activation
[235,236] and inactivation [222,226], possibly dependent on en-
dogenous expression of Nav subunits and other Nav-interacting proteins
in the experimental system used. Navβs are also cell adhesion mole-
cules, owing to the presence of an extracellular immunoglobulin loop
[237–240], which permits NaVβ-mediated neurite outgrowth
[241–244]. NaVβ1 plays an important role in regulating neuronal mi-
gration in CNS development, particularly in the cerebellum [14,245],
and NaVβ2 promotes dendritic expansion during hippocampal devel-
opment via a Navα-independent mechanism [243]. NaVβ subunits are
also substrates for proteolytic processing by secretases [246,247] and
evidence suggests that the cleaved intracellular domain of NaVβ2
shuttles to the nucleus to regulate expression of α-subunit genes [248].
Emerging evidence suggests that Navβs play diverse functional roles
in cancer. Navβ1 is upregulated in breast cancer samples and is more
highly expressed in strongly metastatic, compared to weakly metastatic,
prostate cancer cell lines [249,250]. Overexpression of Navβ1 in the
MDA-MB-231 breast cancer cell line promotes primary tumour growth
and metastasis to multiple organs when grafted into mice, compared to
parental MDA-MB-231 cells [249]. The Navβ1-induced increase in pri-
mary and secondary tumour growth was accompanied by a decrease in
apoptotic cleaved caspase-3 staining, no change in proliferative Ki67
staining, and an increase in endothelial CD31 staining, suggesting in-
creased apoptotic resistance and vascularisation underlie the oncogenic
inﬂuence of Navβ1 [249]. In vitro, MDA-MB-231-Navβ1 cells demon-
strate increased cell-cell adhesion, VGSC-mediated Na+ current and
neurite-like process outgrowth, which is reversible by inhibiting INa
[249,251]. Interestingly, MDA-MB-231-Navβ1 cells show decreased in
vitro motility and proliferation compared to MDA-MB-231 cells and
knockdown of endogenous Navβ1 in the MCF-7 breast cancer cell line
increases cell migration [251]. Similarly, Navβ1 is also expressed in
cervical cancer cells where it inhibits motility [252]. Furthermore,
treatment of mouse melanoma B16F10 cells with the anti-cancer
polymethoxyﬂavone, casticin, inhibits cell migration and invasion and
causes a concomitant genomic upregulation of SCN1B (encoding for
Navβ1) [253]. Navβ1 therefore appears to have a negative inﬂuence on
cell behaviour in vitro and potentially induces tumour growth and
metastasis through an increase in apoptotic resistance and transcellular
adhesion.
Navβ2 also appears to be oncogenic. Navβ2 expression is increased in
strongly metastatic prostate cancer cell lines relative to weakly meta-
static cell lines [254]. Perineural invasion is common in invasive
prostate cancer, and LNCaP prostate cancer cells overexpressing Navβ2
demonstrate an increased association with ex vivo murine spinal cord
axons and an increase in migration, invasion and growth [254,255].
Despite the invasion-promoting behaviour of Navβ2 in vitro, over-
expression of Navβ2 in LNCaP cells inhibits tumour growth, compared
to LNCaP cells, when implanted into mice, suggesting the functional
contribution of Navβ2 might be site or stage-speciﬁc during cancer
progression [255].
Unlike Navβ1 and Navβ2, Navβ3 and Navβ4 are considered tumour-
suppressive. SCN3B (encoding for Navβ3) expression is strongly upre-
gulated by p53 following DNA damage and Navβ3 expression induces
apoptosis and suppresses colony formation in osteosarcoma and glio-
blastoma cell lines [256]. Navβ4 expression is downregulated in thyroid
and high-grade breast cancer and is associated with favourable survival
[231,257]. Downregulation of Navβ4 in MDA-MB-231 breast cancer
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cells with shRNA increases primary tumour growth and metastasis in
xenograft mice models, relative to MDA-MB-231 cells overexpressing
Navβ4 [231]. Furthermore, loss of Navβ4 increases Navα-independent
RhoA-mediated cancer cell migration and invasion [231]. Navβ4 also
suppresses invasion in cervical cancer cells [252]. Navβs are structu-
rally very similar and generally have a broadly comparable eﬀect in-
creasing INa, so it is intriguing that Navβ1 and Navβ2 are oncogenic,
whereas Navβ3 and Navβ4 are tumour-suppressive. Additionally, both
Navβ1 and Navβ4 were investigated using the same breast cancer cell,
MDA-MB-231, so the endogenous VGSC subunit expression accom-
panying the Navβ-subunit is comparable [231,249]. Both Navβ1 and
Navβ4 inhibit cell migration in vitro and induce neurite outgrowth in
developing neurons, thus it is unclear where the functional discrepancy
between the two proteins lies [231,241,251,258].
5. Cl− channels
Cl− channels are a family of relatively poorly understood proteins
that facilitate transmembrane Cl− transport. Cl− concentration is
highest intracellularly and ECl ˜-30 to−60mV, so channels conduct an
outward Cl− current at resting membrane potentials that can reverse on
depolarisation, although inwardly and outwardly rectifying Cl− chan-
nels have been identiﬁed [13]. Cl− channels are involved in regulating
a range of bodily functions, including renal salt retention [259], sy-
naptic inhibition [260], skeletal muscle contraction [261], smooth
muscle tone [262] and sperm motility [263]. Various subfamilies of Cl−
exist, but only the voltage-gated Cl− channel (CLC) and Ca2+-sensitive
Cl− channel (CaCC) subfamilies possess auxiliary subunits with a robust
link to cancer (Fig. 4A, B).
5.1. Voltage-gated Cl− channels
CLCs represent a range of cell surface Cl− channels (ClC-1,2,K) and
intracellular Cl− exchangers (ClC-3-7). Some CLCs are regulated by
auxiliary subunits; ClC-2 by GlialCAM [264,265], ClC-7 by Ostm1
[266], and ClC-K by Barttin [267]. GlialCAM targets ClC-2 to cell-cell
junctions, increases Cl− current (ICl), accelerates ICl activation, and
abolishes ClC-2 inward rectiﬁcation and pH sensitivity [264]. GlialCAM
also functions as a cell adhesion molecule via an extracellular im-
munoglobulin domain [268,269]. ClC-7 is an intracellular, electrogenic
H+/Cl− exchanger involved in lysosomal acidiﬁcation [270]. Inter-
estingly, ClC-7 regulates the traﬃcking and expression of its auxiliary
subunit, Ostm1 [266,271]. Nevertheless, Ostm1 is required to activate
ClC-7 function [270]. Barttin traﬃcs ClC-K to the cell surface, resulting
in increased ICl, and abolishes the voltage-dependence of ClC-K
[272–274]. Mutations in the gene encoding Barttin are the cause of
Bartter syndrome type IV, characterised by hypokalaemia, blood alka-
losis and hypotension [275,276]. Knockin mice with the disease-
causing Barttin mutation R8L present with reduced plasma membrane
Barttin-ClC-K complexes and transepithelial Cl− transport is impaired
in the loop of Henle [277].
GlialCAM (also called HepaCAM) was identiﬁed as a putative tu-
mour suppressor gene that is silenced in hepatocellular carcinoma
[278]. GlialCAM downregulation is observed in liver, bladder, prostate,
kidney, breast, uterus, colon, stomach, and rectal cancer biopsies
[269,278–282]. Functionally, when GlialCAM is expressed in the liver
carcinoma cell line HepG2, cell motility and adhesion are increased,
colony formation is reduced, and proliferation is reduced [278]. Simi-
larly, when expressed in MCF-7 breast cancer cells, GlialCAM increases
cell motility and adhesion, decreases proliferation, and induces p53-
mediated cellular senescence [279,283]. GlialCAM inhibits prolifera-
tion and β-catenin signalling in bladder carcinoma cells [284,285].
Furthermore, in renal carcinoma cells, GlialCAM decreases prolifera-
tion, induces cell cycle arrest, and stimulates c-Myc degradation [286].
GlialCAM expression is also suﬃcient for reducing Notch-mediated
invasion and migration in prostate cancer cells [282]. Lastly, GlialCAM
stabilises connexin-43 at cell-cell gap junctions [287], connexin-43
being a potential tumour suppressor itself [288,289]. In summary,
GlialCAM has a strong anti-proliferative inﬂuence when expressed in
cancer cells, which could underpin its role as a tumour suppressor.
5.2. Ca2+-sensitive Cl− channels
Four single membrane-pass auxiliary subunits of CaCCs have been
identiﬁed (known as Ca2+-activated Cl− channel regulator or Cl−
channel accessory [CLCA]1-4) [290,291]. Interestingly, the molecular
identities of the conducting subunits were only discovered later and
termed Best1-4 and TMEM16 [292–295]. CaCCs demonstrate voltage-
dependence at steady-state, which is abolished following an increase in
[Ca2+]i [296]. Increased [Ca
2+]i also increases ICl and accelerates
current onset [296]. CaCCs are expressed in epithelia and excitable
tissues, where they regulate excitability [297], smooth muscle con-
traction [298] and ﬂuid secretion [299]. Expression of CLCA1 and
CLCA2 in HEK293 cells induces an enlarged and outwardly-rectifying
ICaCC [290,300]. More recent work has demonstrated that the secreted
N-terminus of CLCA1, produced following autoproteolysis, is suﬃcient
to stabilise TMEM16 A at the membrane, increasing ICaCC [301–303].
CLCA1 contains an intrinsic metalloprotease domain in the N-terminus
Fig. 3. Voltage-gated Na+ channel auxiliary subunits.
Voltage-gated Na+ channels (VGSCs) contain a conducting
Navα subunit and auxiliary Navβ subunits. Navα consists of
four domains (domains I-IV), each containing six segments
(S1-S6). The voltage-sensing domain is found within S4 of
each domain and the pore consists of the P-loop found
between S5-6 of each domain. Navβs function as cell ad-
hesion molecules via an extracellular immunoglobulin
domain [238,239,332]. Navβs also induce neurite out-
growth and migration [245] and the intracellular domain
of Navβ2 has putative transcription regulation function
[248].
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that is thought to be responsible for autoproteolysis and regulating
mucus turnover in the colon [304]. Despite CLCA2 enlarging ICaCC,
CLCA2 does not interact directly with TMEM16 or Best1 [305]. Instead,
CLCA2 interacts directly with store-operated Ca2+ channels, Orai1 and
STIM-1, stimulating ER Ca2+ replenishment following cytosolic deple-
tion [305].
CLCAs have a well-documented tumour-suppressive role [306–308].
CLCA1 is downregulated in colorectal and pancreatic cancer specimens
[306,309–311]. CLCA1 knockdown induces proliferation and inhibits
diﬀerentiation of caco-2 colorectal cancer cells [311]. Furthermore,
CLCA1 overexpression inhibits Wnt signalling and colorectal tumour
growth and metastasis in vivo [306]. CLCA2 expression is also decreased
in high-grade nasopharyngeal, colorectal, lymphoid and breast cancer
specimens compared to low grade samples [307,312–314]. Expression
of CLCA2 decreases nasopharyngeal and breast tumourigenesis in vivo
[307,312,315]. Similarly, CLCA2 depletion increases the number of
circulating prostate tumour cells in mice [316]. At a cellular level,
CLCA2 inhibits Wnt signalling [317], decreases invasion [315], inhibits
proliferation [312], induces transcellular adhesion [316], inhibits epi-
thelial-to-mesenchymal transition [312,316], induces diﬀerentiation
[316,318], inhibits focal adhesion kinase [312,319] and induces p53-
mediated cellular senescence [320]. The ability of CLCA2 to inhibit
cancer cell migration appears to be ICl independent, as inhibiting ICl has
a further anti-migratory eﬀect in cells expressing CLCA2 as well as
having an anti-migratory eﬀect in cells not expressing CLCA2 [312].
Ramena et al. observed CLCA2 at cell-cell junctions, interacting with
EVA1/ZO-1 or β-catenin [317]. Sequestration of β-catenin at the
plasma membrane was therefore suggested as a mechanism for CLCA2-
induced inhibition of epithelial-to-mesenchymal transition. CLCA4 ex-
pression is decreased in bladder, hepatocellular and breast cancer
specimens compared to adjacent normal tissue [308,321,322]. CLCA4
expression also decreases tumourigenicity in mice [321]. Furthermore,
CLCA4 depletion induces epithelial-to-mesenchymal transition via
PI3K/Akt signalling [308,322]. Despite the abundance of evidence
implicating CLCAs as tumour suppressor genes, CLCAs have also been
implicated in induction of lung colonization in vivo via adhesive inter-
actions between endothelial CLCA and β4 integrin expressed on circu-
lating cancer cells [323,324]. Similarly, increased CLCA2 expression is
seen in circulating lung adenocarcinoma cells and ovarian cancer cell
aggregates [325,326], suggesting CLCAs may potentially be tumour
suppressors on the one hand, and metastasis-promoting on the other.
6. Conclusion
Many ion channel auxiliary subunits are upregulated, e.g. Cavβs, or
downregulated, e.g. Kvβs, in tumours and thus may represent novel
cancer biomarkers. in vitro and in vivo experimentation has further
implicated various auxiliary subunits in tumour formation and pro-
gression, such as Navβ1 and α2δ1 (Fig. 5). However, others, e.g. CLCAs,
NaVβ3/4, may function as tumour suppressors. Clearly, it is important
from a treatment perspective to understand the mechanistic function of
ion channel auxiliary subunits, including the extent that they contribute
to cancer progression through potentiating ion conductance or via non-
conducting signalling. For example, α2δ1- and α2δ2-induced Ca
2+
Fig. 4. Cl− channel auxiliary subunits. (A) CLCs are a
subfamily of voltage-sensitive Cl− channels and trans-
porters found at the plasma membrane and internal
membranes [13]. Barttin modulates ClC-K, GlialCAM
modulates ClC-2 and Ostm1 modulates the intracellular
ClC-7 transporter [264,266,267]. CLCs are composed of
eighteen helical domains and two C-terminal cystathio-
nine-β-synthase (CBS) domains which facilitate dimeriza-
tion [333]. Depicted is the plasma membrane ClC-2 which
interacts with single-pass GlialCAM, the only ClC auxiliary
subunit implicated in cancer [264]. GlialCAM can also
function as a cell adhesion molecule [268]. (B) Two se-
parate CaCC conducting subunits exist- TMEM16 and Be-
strophin. Depicted is eight-pass TMEM16 A which is
modulated directly by secreted CLCA1 and indirectly by
single-pass CLCA2 [303,305]. CLCA2 stimulates Ca2+
store replenishment by interacting with Orai1 and STIM1
[305].
A.S. Haworth and W.J. Brackenbury &HOO&DOFLXP²

inﬂux may promote hepatocellular carcinoma cell sphere formation and
pancreatic adenoma proliferation respectively [71,83]. Other examples
include NaVα-dependent, NaVβ1-mediated process outgrowth and the
extent of glibenaclamide-induced inhibition of SUR2-mediated cancer
cell proliferation correlating with the mRNA expression of Kir6.2
[213,249]. Validating the contribution of ion conductance to the on-
cogenic function of these auxiliary subunits would provide a potential
therapeutic target, as many ion channel inhibitors are already in clin-
ical use and could be repurposed [327–329]. On the other hand, nu-
merous auxiliary subunits many regulate cancer progression via non-
conducting roles, e.g. regulation of transcription, proliferation and
diﬀerentiation by Cavβ1 and KChIP3 [36,172]. Various auxiliary sub-
units also function as adhesion molecules in cancer cells, e.g. GlialCAM,
CLCAs and Navβs [254,278,316]. Further work is required to fully de-
lineate the diverse functional contributions of these subunits to carci-
nogenesis, tumour progression and metastasis, and understand their
potential as novel therapeutic targets.
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